Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn MoreThe brain tumor is a generic or common name for intracranial tumors. Brain tumors can occur at any age. In recent years, the incidence of brain tumors is on the rise, and many brain tumors are already large when they are detected, and even benign tumor surgery has great risks. Therefore, early detection, early treatment, and in-depth research on brain tumors appear to be crucial. The establishment of brain tumor cell lines is of great theoretical and clinical importance for studying the molecular mechanisms and biological characteristics of brain tumor carcinogenesis, invasion and metastasis, multidrug resistance, and the development of new anti-brain tumor drugs.
During the survival of a cell line, cells with the highest growth capacity will dominate, resulting in a cell population that can achieve a certain degree of homogeneity in genotype and phenotype. Cell lines are more homogeneous and standardized than primary cultured cells and have an important role in brain tumor drug screening and toxicology studies. Alfa Cytology can provide our clients with a variety of cell line development services, including reporter gene functional cell lines, stable cell lines, glioblastoma cell lines, meningioma cell lines, and astroglioma cell lines. Because of their unlimited proliferative capacity and plasticity in generating various cell types, stem cells have great potential in developmental biology and disease modeling compared to primary cells and cell lines. Therefore, we are also working on the development of brain tumor stem cells. This complete system can meet your multiple needs for brain tumor drug screening and disease research.
We can customize the development of reporter gene functional cell lines to meet customer needs. It can eliminate the need for primary cell culture and overcome the limitations of traditional methods and is suitable for large-scale high-throughput brain tumor antibody drug screening, bioactivity assay, and stability determination.
We screen target cells for resistance markers on a transient transfection basis. Alternatively, high transfection efficiency viruses are used to select the appropriate drugs for cell passaging according to the resistance markers contained in the different gene vectors. This results in cell lines that can stably express the target gene in a short period.
We provide brain tumor stem cell development methods and analysis services that can explain the differentiation path of brain tumor stem cells, help you develop newer brain tumor treatment strategies, and accelerate research on brain tumor growth, dissemination, recurrence, targeted therapeutic approaches, etc.
The GBM cell lines we develop can either be used directly as in vitro anti-GBM drug screening models or can be used to obtain highly tumorigenic human GBM animal models by multiple passages in mammals such as immunodeficient mice. This will help you to establish two related anti-GBM drug screening platforms in vitro and in vivo.
We can culture stable malignant meningioma primary cells to isolate and culture meningioma cell lines of uniform cell quality. We can also perform cell viability and cell morphology assays by MTT and bright-field microscopy and examine adhesion chemotaxis, and invasion by real-time cell analysis.
We have an astrocytoma cell line development service that can help you find valuable biomarker molecules for brain astrocytoma and, hopefully, identify candidate targets for gene therapy of malignant brain astrocytoma, providing a new strategy for gene therapy of brain malignant astrocytoma.
Alfa Cytology uses brain tumor samples to establish brain tumor cell lines through a series of methods such as the primary culture of intact tissue blocks, subcutaneous graft tumor model construction, and primary culture of subcutaneous graft tumors. Our established brain tumor cell lines have been cultured in vitro for more than six months with stable growth, continuous passages, clear cell growth characteristics, genetic analysis, tumor marker assay, xenograft tumorigenicity assay, and no contamination. Please contact our staff to learn how our established brain tumor cell lines can provide valuable information for our clients to conduct research on the pathogenesis of brain tumors, find useful indicators for diagnosing brain tumors and explore experimental therapeutic options.